Indoco Remedies Overview
- Year Founded
-
1947
- Status
-
Public
- Employees
-
6,000
- Stock Symbol
-
532612
- Investments
-
5
- Share Price
-
$4.78
- (As of Wednesday Closing)
Indoco Remedies General Information
Description
Indoco Remedies Ltd is an India based pharmaceutical company. It is engaged in the manufacturing and marketing of formulations (finished dosage forms) and active pharmaceutical ingredients (APIs). Its manufacturing products for different therapeutic segments including respiratory, stomatology, women's health, nutritional products, gastroenterology, cardiology, metabolic disorders, and primary care medicines. Geographically, it generates the majority of the revenue from India.
Contact Information
- 166 Indoco House
- C S T Road, Santacruz East
- Mumbai, Maharashtra 400098
- India
Indoco Remedies Stock Performance
(As of Wednesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $4.78 | $4.62 | $3.71 - $5.11 | $440M | 92.2M | 16K | $0.15 |
Indoco Remedies Financials Summary
|
In Thousands, USD |
TTM 30-Sep-2023 | FY 2023 31-Mar-2023 | FY 2022 31-Mar-2022 | FY 2021 31-Mar-2021 |
|---|---|---|---|---|
| EV | 413,530 | 391,760 | 487,410 | 384,356 |
| Revenue | 210,286 | 204,246 | 201,823 | 163,792 |
| EBITDA | 32,209 | 35,921 | 44,247 | 30,292 |
| Net Income | 13,783 | 17,715 | 20,776 | 12,506 |
| Total Assets | 232,915 | 201,971 | 195,981 | 179,052 |
| Total Debt | 59,613 | 40,542 | 33,848 | 36,318 |
Indoco Remedies Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Indoco Remedies Patents
Indoco Remedies Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-3523307-A4 | Process for the preparation of doraolzmide hydrochloride | Active | 07-Oct-2016 | 0000000000 | 0 |
| EP-3523307-A1 | Process for the preparation of doraolzmide hydrochloride | Active | 07-Oct-2016 | 0000000000 | |
| EP-3523307-B1 | Process for the preparation of doraolzmide hydrochloride | Active | 07-Oct-2016 | 0000000000 | |
| EP-3292112-A1 | Process for the preparation of alogliptin | Active | 04-May-2015 | 0000000000 | |
| EP-3292112-B1 | Process for the preparation of alogliptin | Active | 04-May-2015 | C07D401/04 |
Indoco Remedies Executive Team (6)
Indoco Remedies Board Members (6)
| Name | Representing | Role | Since |
|---|---|---|---|
| 00000 0000000000 | Indoco Remedies | Joint Managing Director & Board Member | 000 0000 |
| 00000 00000000 | Indoco Remedies | Board Member | 000 0000 |
| 00000 00000000 | Indoco Remedies | Board Member | 000 0000 |
| 0000000 000000000 | Indoco Remedies | Joint Managing Director & Board Member | 000 0000 |
| 000000 0000 | Indoco Remedies | Chairman | 000 0000 |
Indoco Remedies Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Indoco Remedies Investments & Acquisitions (5)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Florida Pharmaceutical Products | 06-Jun-2023 | 0000000000 | 000 | Pharmaceuticals | 00000 000 |
| Jalansar Wind Energy | 30-Sep-2022 | 000000000 | 00000 | Special Purpose Acquisition Company (SPAC) | 00000 000 |
| Micro Labs (Pharmaceutical Plant Baddi) | 21-Sep-2016 | 000000000 | Buildings and Property | 00000 000 | |
| Piramal (clinical research division) | 06-Apr-2015 | 0000000000 | Laboratory Services (Healthcare) | 00000 000 | |
| La Nova Chem | 04-Jul-2006 | Merger/Acquisition | Pharmaceuticals |
Indoco Remedies Subsidiaries (1)
| Company Name | Industry | Location | Founded |
|---|---|---|---|
| Florida Pharmaceutical Products | Pharmaceuticals | Boca Raton, FL | 0000 |
Indoco Remedies ESG
Risk Overview
Risk Rating
Updated October, 11, 2023
37.18 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
00.0
Management
Management is related to actions taken to manage ESG issues
00.00
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
00 of 15,708
Rank
Percentile
Pharmaceuticals
Industry
00 of 884
Rank
Percentile
Pharmaceuticals
Subindustry
00 of 418
Rank
Percentile
